This is marked by alterations in the levels and/or expression areas of both CB1R and CB2R. Initially, CB1R expression increases in the frontal cortex and hippocampus during the early stages of AD, but decreases progressively over time. This evidence concerns the gene CNR1 and Alzheimer disease.